KvLQT3

Knopp Biosciences to Present Data on Its Potassium Channel Activator Program at 2019 Antiepileptic Drug and Device Trials XV Conference

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Other Health, Research, FDA, Science, Branches of biology, Biology, Ion channels, Proteins, Epilepsy, KvLQT3, Epileptic seizure, KvLQT2

KCNQ2-NEE, a rare genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and abnormal brain development.

Key Points: 
  • KCNQ2-NEE, a rare genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and abnormal brain development.
  • Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other unmet needs in diseases of the nervous system.
  • Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need.
  • Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration.